John T. James
John T. James has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Bonnie L Cooper
Jacobs Technology, 2224 Bay Area Boulevard, Houston, 77058, TX
1 shared publication Bruce O. Stuart
Mantech Environmental Technology, Inc., Dayton, Ohio, USA
1 shared publicationChiu-Wing Lam
Wyle Science, Technology & Engineering Group Houston, TXUSA
1 shared publication- Chiu-Wing Lam
Wyle Laboratories, NASA Johnson Space Center, Houston, Texas 77058, USA
1 shared publication Darol E. Dodd
ManTech Environmental Technology, Inc., Dayton, Ohio
1 shared publicationDarwin Jay Eakins
University of Kansas, Lawrence, Kansas, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2022
- Published by SAGE Publications in Journal of Patient Experience
- Vol. 9
Abandon Informed Consent in Favor of Probability-Based, Shared Decision-Making Following the Wishes of a Reasonable Person
Legally and ethically physicians must provide information to patients so they may make an informed decision about invasive procedures. The problem is who decides what information to provide. Is it the reasonable patient or the reasonable physician? Individual patients and individual physicians may differ from the norm on what is reasonable. This problem may be solved by shared decision-making in which the preferences of the patient and the probability-based knowledge of the physician are used to co-produce an optimal choice. Currently, patients are seldom prepared to engage in shared decision-making, and vestiges of meaningless “informed consent” are common. The present case study illustrates how “reasonable person” survey data may be used by a patient to engage in probability-based, shared decision-making with a surgeon planning to perform a laminectomy. Recommendations include probability-based, shared decision-making training for patients and physicians and improved documentation to facilitate learning.
- 1 January 2022
- Published by SAGE Publications in Journal of Patient Experience
- Vol. 9
Open AccessAbandon Informed Consent in Favor of Probability-Based, Shared Decision-Making Following the Wishes of a Reasonable Person
Legally and ethically physicians must provide information to patients so they may make an informed decision about invasive procedures. The problem is who decides what information to provide. Is it the reasonable patient or the reasonable physician? Individual patients and individual physicians may differ from the norm on what is reasonable. This problem may be solved by shared decision-making in which the preferences of the patient and the probability-based knowledge of the physician are used to co-produce an optimal choice. Currently, patients are seldom prepared to engage in shared decision-making, and vestiges of meaningless “informed consent” are common. The present case study illustrates how “reasonable person” survey data may be used by a patient to engage in probability-based, shared decision-making with a surgeon planning to perform a laminectomy. Recommendations include probability-based, shared decision-making training for patients and physicians and improved documentation to facilitate learning.
- Open Access
Informed consent, shared-decision making and a reasonable patient’s wishes based on a cross-sectional, national survey in the USA using a hypothetical scenario
Objective In approximately half the states in the USA, and more recently in the UK, informed consent is legally defined as what a reasonable patient would wish to know. Our objective was to discern the information needs of a hospitalised, ‘reasonable patient’ during the informed-consent process. Design We performed a cross-sectional study to develop a survey instrument and better define ‘reasonable person’ in relation to informed consent in a hypothetical scenario where an invasive procedure may be an option. Setting A 10-question survey was administered from April 19 through 22 October 2018 to three groups: student nurses (n=76), health professions educators (n=63) and a US national population (n=1067). Primary and secondary outcome measures The primary outcome measure was the average intensity, on a 5-point scale, by which survey groups wished to have each of 10 questions answered. The secondary outcome was to discern relationships between survey demographics and the intensity by which participants wanted an answer. Results Despite substantial demographic differences in the nursing-student group and health-professions-educator group, the average intensity scores were within 0.2 units on nine of 10 questions. The national survey revealed a strong desire to have an answer to each question (range 3.98–4.60 units). It showed that women desired answers more than men and older adults desired answers more than younger adults. Conclusions Based on responses to 10 survey questions regarding wishes of people in a situation where an invasive procedure may be necessary, the vast majority want an answer to each question. They wanted to know about all treatment options, risky drugs, decision aids, who will perform the procedure, and the cost. They wanted their advocate present, periodic review of their medical record, a full day to review documents and expected outcomes and restrictions after the procedure.
Open AccessInformed consent, shared-decision making and a reasonable patient’s wishes based on a cross-sectional, national survey in the USA using a hypothetical scenario
Objective In approximately half the states in the USA, and more recently in the UK, informed consent is legally defined as what a reasonable patient would wish to know. Our objective was to discern the information needs of a hospitalised, ‘reasonable patient’ during the informed-consent process. Design We performed a cross-sectional study to develop a survey instrument and better define ‘reasonable person’ in relation to informed consent in a hypothetical scenario where an invasive procedure may be an option. Setting A 10-question survey was administered from April 19 through 22 October 2018 to three groups: student nurses (n=76), health professions educators (n=63) and a US national population (n=1067). Primary and secondary outcome measures The primary outcome measure was the average intensity, on a 5-point scale, by which survey groups wished to have each of 10 questions answered. The secondary outcome was to discern relationships between survey demographics and the intensity by which participants wanted an answer. Results Despite substantial demographic differences in the nursing-student group and health-professions-educator group, the average intensity scores were within 0.2 units on nine of 10 questions. The national survey revealed a strong desire to have an answer to each question (range 3.98–4.60 units). It showed that women desired answers more than men and older adults desired answers more than younger adults. Conclusions Based on responses to 10 survey questions regarding wishes of people in a situation where an invasive procedure may be necessary, the vast majority want an answer to each question. They wanted to know about all treatment options, risky drugs, decision aids, who will perform the procedure, and the cost. They wanted their advocate present, periodic review of their medical record, a full day to review documents and expected outcomes and restrictions after the procedure.
- 15 December 2016
- Published by Springer Nature
- p. 137-153
Toxicology
- Top Cited Papers
- 1 September 2013
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 9 (3) , 122-128
A New, Evidence-based Estimate of Patient Harms Associated with Hospital Care
Based on 1984 data developed from reviews of medical records of patients treated in New York hospitals, the Institute of Medicine estimated that up to 98,000 Americans die each year from medical errors. The basis of this estimate is nearly 3 decades old; herein, an updated estimate is developed from modern studies published from 2008 to 2011. A literature review identified 4 limited studies that used primarily the Global Trigger Tool to flag specific evidence in medical records, such as medication stop orders or abnormal laboratory results, which point to an adverse event that may have harmed a patient. Ultimately, a physician must concur on the findings of an adverse event and then classify the severity of patient harm. Using a weighted average of the 4 studies, a lower limit of 210,000 deaths per year was associated with preventable harm in hospitals. Given limitations in the search capability of the Global Trigger Tool and the incompleteness of medical records on which the Tool depends, the true number of premature deaths associated with preventable harm to patients was estimated at more than 400,000 per year. Serious harm seems to be 10- to 20-fold more common than lethal harm. The epidemic of patient harm in hospitals must be taken more seriously if it is to be curtailed. Fully engaging patients and their advocates during hospital care, systematically seeking the patients' voice in identifying harms, transparent accountability for harm, and intentional correction of root causes of harm will be necessary to accomplish this goal.
- 1 September 2013
- Published by Wolters Kluwer Health in Journal of Patient Safety
- Vol. 9 (3) , 122-128
Top Cited PapersA New, Evidence-based Estimate of Patient Harms Associated with Hospital Care
Based on 1984 data developed from reviews of medical records of patients treated in New York hospitals, the Institute of Medicine estimated that up to 98,000 Americans die each year from medical errors. The basis of this estimate is nearly 3 decades old; herein, an updated estimate is developed from modern studies published from 2008 to 2011. A literature review identified 4 limited studies that used primarily the Global Trigger Tool to flag specific evidence in medical records, such as medication stop orders or abnormal laboratory results, which point to an adverse event that may have harmed a patient. Ultimately, a physician must concur on the findings of an adverse event and then classify the severity of patient harm. Using a weighted average of the 4 studies, a lower limit of 210,000 deaths per year was associated with preventable harm in hospitals. Given limitations in the search capability of the Global Trigger Tool and the incompleteness of medical records on which the Tool depends, the true number of premature deaths associated with preventable harm to patients was estimated at more than 400,000 per year. Serious harm seems to be 10- to 20-fold more common than lethal harm. The epidemic of patient harm in hospitals must be taken more seriously if it is to be curtailed. Fully engaging patients and their advocates during hospital care, systematically seeking the patients' voice in identifying harms, transparent accountability for harm, and intentional correction of root causes of harm will be necessary to accomplish this goal.
- 24 April 2013
- Published by Taylor & Francis in Inhalation Toxicology
- Vol. 25 (5) , 243-256
Estimate of safe human exposure levels for lunar dust based on comparative benchmark dose modeling
Brief exposures of Apollo astronauts to lunar dust occasionally elicited upper respiratory irritation; however, no limits were ever set for prolonged exposure to lunar dust. The United States and other space faring nations intend to return to the moon for extensive exploration within a few decades. In the meantime, habitats for that exploration, whether mobile or fixed, must be designed to limit human exposure to lunar dust to safe levels. Herein we estimate safe exposure limits for lunar dust collected during the Apollo 14 mission. We instilled three respirable-sized (∼2 μ mass median diameter) lunar dusts (two ground and one unground) and two standard dusts of widely different toxicities (quartz and TiO2) into the respiratory system of rats. Rats in groups of six were given 0, 1, 2.5 or 7.5 mg of the test dust in a saline-Survanta® vehicle, and biochemical and cellular biomarkers of toxicity in lung lavage fluid were assayed 1 week and one month after instillation. By comparing the dose--response curves of sensitive biomarkers, we estimated safe exposure levels for astronauts and concluded that unground lunar dust and dust ground by two different methods were not toxicologically distinguishable. The safe exposure estimates were 1.3 ± 0.4 mg/m3 (jet-milled dust), 1.0 ± 0.5 mg/m3 (ball-milled dust) and 0.9 ± 0.3 mg/m3 (unground, natural dust). We estimate that 0.5–1 mg/m3 of lunar dust is safe for periodic human exposures during long stays in habitats on the lunar surface.
- 24 April 2013
- Published by Taylor & Francis in Inhalation Toxicology
- Vol. 25 (5) , 243-256
Estimate of safe human exposure levels for lunar dust based on comparative benchmark dose modeling
Brief exposures of Apollo astronauts to lunar dust occasionally elicited upper respiratory irritation; however, no limits were ever set for prolonged exposure to lunar dust. The United States and other space faring nations intend to return to the moon for extensive exploration within a few decades. In the meantime, habitats for that exploration, whether mobile or fixed, must be designed to limit human exposure to lunar dust to safe levels. Herein we estimate safe exposure limits for lunar dust collected during the Apollo 14 mission. We instilled three respirable-sized (∼2 μ mass median diameter) lunar dusts (two ground and one unground) and two standard dusts of widely different toxicities (quartz and TiO2) into the respiratory system of rats. Rats in groups of six were given 0, 1, 2.5 or 7.5 mg of the test dust in a saline-Survanta® vehicle, and biochemical and cellular biomarkers of toxicity in lung lavage fluid were assayed 1 week and one month after instillation. By comparing the dose--response curves of sensitive biomarkers, we estimated safe exposure levels for astronauts and concluded that unground lunar dust and dust ground by two different methods were not toxicologically distinguishable. The safe exposure estimates were 1.3 ± 0.4 mg/m3 (jet-milled dust), 1.0 ± 0.5 mg/m3 (ball-milled dust) and 0.9 ± 0.3 mg/m3 (unground, natural dust). We estimate that 0.5–1 mg/m3 of lunar dust is safe for periodic human exposures during long stays in habitats on the lunar surface.
- 1 August 2012
- Published by Aerospace Medical Association in Aviation, Space, and Environmental Medicine
- Vol. 83 (8) , 795-799
Prediction of crew health effects from air samples taken aboard the International Space Station.
James JT, Zalesak SM. Prediction of crew health effects from air samples taken aboard the International Space Station. Aviat Space Environ Med 2012; 83:795–9. Introduction: Spaceflight aboard the International Space Station (ISS) involves stays of individual crewmembers for up to 6 mo during which they are exposed to a complex mixture of airborne pollutants. Methods to predict specific health effects from exposure to a mixture of air pollutants are not well developed. Herein, air monitoring data from the ISS are used to demonstrate a new method to estimate a threshold for possible health effects from exposure to mixtures. Methods: An empirical, additive approach was developed to transform monthly air pollutant data, which had been obtained primarily by gas chromatography-mass spectrometry from samples of ISS air, to threshold (T) values for 16 adverse health effect groups. Spacecraft maximum allowable concentrations (SMACs), available for most spacecraft air pollutants, were used to form target-organ/effect groups, from which group T values were estimated. If T > 1 for a group, then there is an unacceptable risk of the toxic effect. Results: Samples of air taken from the ISS in 2010 revealed that all 16 toxicological groups were within safe limits. Highest T values were as follows: mucosal irritants (0.53 ± 0.44), headache (0.52 ± 0.06), central nervous system depression (0.25 ± 0.06), and cardiac sensitization (0.13 ± 0.04). Discussion: The additive model is supported by limited inhalation data on rats in the literature. Our predictions of no adverse effect on crew health are useful as part of NASA’s Lifetime Surveillance of Astronaut Health (LSAH). If one of the 16 levels had exceeded T = 1, then standard surveillance could be supplemented to address this potential health risk.
- 1 August 2012
- Published by Aerospace Medical Association in Aviation, Space, and Environmental Medicine
- Vol. 83 (8) , 795-799
Prediction of crew health effects from air samples taken aboard the International Space Station.
James JT, Zalesak SM. Prediction of crew health effects from air samples taken aboard the International Space Station. Aviat Space Environ Med 2012; 83:795–9. Introduction: Spaceflight aboard the International Space Station (ISS) involves stays of individual crewmembers for up to 6 mo during which they are exposed to a complex mixture of airborne pollutants. Methods to predict specific health effects from exposure to a mixture of air pollutants are not well developed. Herein, air monitoring data from the ISS are used to demonstrate a new method to estimate a threshold for possible health effects from exposure to mixtures. Methods: An empirical, additive approach was developed to transform monthly air pollutant data, which had been obtained primarily by gas chromatography-mass spectrometry from samples of ISS air, to threshold (T) values for 16 adverse health effect groups. Spacecraft maximum allowable concentrations (SMACs), available for most spacecraft air pollutants, were used to form target-organ/effect groups, from which group T values were estimated. If T > 1 for a group, then there is an unacceptable risk of the toxic effect. Results: Samples of air taken from the ISS in 2010 revealed that all 16 toxicological groups were within safe limits. Highest T values were as follows: mucosal irritants (0.53 ± 0.44), headache (0.52 ± 0.06), central nervous system depression (0.25 ± 0.06), and cardiac sensitization (0.13 ± 0.04). Discussion: The additive model is supported by limited inhalation data on rats in the literature. Our predictions of no adverse effect on crew health are useful as part of NASA’s Lifetime Surveillance of Astronaut Health (LSAH). If one of the 16 levels had exceeded T = 1, then standard surveillance could be supplemented to address this potential health risk.
- Open Access
- 20 July 2012
- Published by Springer Nature in BMC Ophthalmology
- Vol. 12 (1) , 26
Ocular toxicity of authentic lunar dust
Background: Dust exposure is a well-known occupational hazard for terrestrial workers and astronauts alike and will continue to be a concern as humankind pursues exploration and habitation of objects beyond Earth. Humankind’s limited exploration experience with the Apollo Program indicates that exposure to dust will be unavoidable. Therefore, NASA must assess potential toxicity and recommend appropriate mitigation measures to ensure that explorers are adequately protected. Visual acuity is critical during exploration activities and operations aboard spacecraft. Therefore, the present research was performed to ascertain the ocular toxicity of authentic lunar dust.Methods: Small (mean particle diameter = 2.9 ± 1.0 μm), reactive lunar dust particles were produced by grinding bulk dust under ultrapure nitrogen conditions. Chemical reactivity and cytotoxicity testing were performed using the commercially available EpiOcularTMassay. Subsequentin vivoDraize testing utilized a larger size fraction of unground lunar dust that is more relevant to ocular exposures (particles In vitrotesting indicated minimal irritancy potential based on the time required to reduce cell viability by 50% (ET50). Follow-up testing using the Draize standard protocol confirmed that the lunar dust was minimally irritating. Minor irritation of the upper eyelids was noted at the 1-hour observation point, but these effects resolved within 24 hours. In addition, no corneal scratching was observed using fluorescein stain.Conclusions: Low-titanium mare lunar dust is minimally irritating to the eyes and is considered a nuisance dust for ocular exposure. No special precautions are recommended to protect against ocular exposures, but fully shielded goggles may be used if dust becomes a nuisance.
- 20 July 2012
- Published by Springer Nature in BMC Ophthalmology
- Vol. 12 (1) , 26
Open AccessOcular toxicity of authentic lunar dust
Background: Dust exposure is a well-known occupational hazard for terrestrial workers and astronauts alike and will continue to be a concern as humankind pursues exploration and habitation of objects beyond Earth. Humankind’s limited exploration experience with the Apollo Program indicates that exposure to dust will be unavoidable. Therefore, NASA must assess potential toxicity and recommend appropriate mitigation measures to ensure that explorers are adequately protected. Visual acuity is critical during exploration activities and operations aboard spacecraft. Therefore, the present research was performed to ascertain the ocular toxicity of authentic lunar dust.Methods: Small (mean particle diameter = 2.9 ± 1.0 μm), reactive lunar dust particles were produced by grinding bulk dust under ultrapure nitrogen conditions. Chemical reactivity and cytotoxicity testing were performed using the commercially available EpiOcularTMassay. Subsequentin vivoDraize testing utilized a larger size fraction of unground lunar dust that is more relevant to ocular exposures (particles In vitrotesting indicated minimal irritancy potential based on the time required to reduce cell viability by 50% (ET50). Follow-up testing using the Draize standard protocol confirmed that the lunar dust was minimally irritating. Minor irritation of the upper eyelids was noted at the 1-hour observation point, but these effects resolved within 24 hours. In addition, no corneal scratching was observed using fluorescein stain.Conclusions: Low-titanium mare lunar dust is minimally irritating to the eyes and is considered a nuisance dust for ocular exposure. No special precautions are recommended to protect against ocular exposures, but fully shielded goggles may be used if dust becomes a nuisance.
- 9 July 2001
- Published by SAE International in SAE International Journal of Advances and Current Practices in Mobility
- Vol. 1
Toxicological Assessment of the International Space Station Atmosphere, Part 2
Space-faring crews must have safe breathing air throughout their missions to ensure adequate performance and good health. Toxicological assessment of air quality depends on the standards that define acceptable air quality, measurements of pollutant levels during the flight, and reports from the crew on their in-flight perceptions of air quality. Air samples from ISS flights 2A.2a, 2A.2b, 3A, and 4A were analyzed for trace pollutants. On average the air during each flight was safe for human respiration. However, there were reports from the crew that they experienced a headache when in certain areas, and strong odors were reported from specific locations of the ISS complex. Inspection of air samples in these locations suggested that several of the solvent-type pollutants (e.g. ethyl acetate, xylenes, and n-butanol) were present in concentrations that would cause a strong odor to be perceived by some individuals. There were large variations in pollutants from selected modules upon first entry; however, the egress samples from each module showed nearly uniform mixing of the atmospheres by the time the ISS was resealed. The Service Module was added during this period and samples of its unscrubbed atmosphere and scrubbed atmosphere show that scrubbing was effective, especially against pollutants that were present in relatively high concentrations.
- 9 July 2001
- Published by SAE International in SAE International Journal of Advances and Current Practices in Mobility
- Vol. 1
Toxicological Assessment of the International Space Station Atmosphere, Part 2
Space-faring crews must have safe breathing air throughout their missions to ensure adequate performance and good health. Toxicological assessment of air quality depends on the standards that define acceptable air quality, measurements of pollutant levels during the flight, and reports from the crew on their in-flight perceptions of air quality. Air samples from ISS flights 2A.2a, 2A.2b, 3A, and 4A were analyzed for trace pollutants. On average the air during each flight was safe for human respiration. However, there were reports from the crew that they experienced a headache when in certain areas, and strong odors were reported from specific locations of the ISS complex. Inspection of air samples in these locations suggested that several of the solvent-type pollutants (e.g. ethyl acetate, xylenes, and n-butanol) were present in concentrations that would cause a strong odor to be perceived by some individuals. There were large variations in pollutants from selected modules upon first entry; however, the egress samples from each module showed nearly uniform mixing of the atmospheres by the time the ISS was resealed. The Service Module was added during this period and samples of its unscrubbed atmosphere and scrubbed atmosphere show that scrubbing was effective, especially against pollutants that were present in relatively high concentrations.
- 1 January 1994
- Published by Taylor & Francis in Inhalation Toxicology
- Vol. 6 (2) , 151-166
Acute, 2-Week, and 13-Week Inhalation Toxicity Studies on Dimethylethoxysilane Vapor in Fischer 344 Rats
Dimethylethoxysilane (DMES), a volatile liquid, is used by NASA to waterproof the heat-protective silica tiles and blankets on the Space Shuttle. Acute, 2-wk, and 13-wk inhalation exposures to DMES vapor were conducted in male and female Fischer 344 rats. In the acute study, rats were exposed to 4000, 2000, 1000, 500, or 0 (control) ppm DMES for 4 h and observed for 14 days. There were no deaths. Narcosis and ataxia were observed in rats of the two highest concentrations only. These signs disappeared within 1 h following exposure. There were no DMES-related gross or microscopic tissue lesions in rats of all exposure groups. In the 2-wk study, rats were exposed for 6 h/day, 5 days/wk to 3000, 1000, 300, 100, or 0 ppm DMES. During exposure, narcosis was observed in rats of the 3000 and 1000 ppm groups. There was a mild decrease in body weight gain in rats of the 3000 ppm group. A decrease in platelet count, an increase in bile acids, and reduced weights of the thymus, testis, and liver were observed in rats of the 3000 ppm group. Microscopically, hypospermatogenesis and spermatid giant cells were observed in the seminiferous tubules of the testes of rats exposed to 3000 ppm DMES. In the 13-wk study, rats were exposed 6 h/day, 5 days/wk to 2000, 600, 160, 40, or 0 ppm DMES. During exposure, rats of the 2000 ppm group exhibited mild narcosis and loss of startle reflex. Recovery from these central nervous system signs was rapid. Body weights were mildly decreased for rats of the 2000 ppm group. There were no exposure-related effects in hematology, serum chemistry, or urinalysis. Female rats of the 2000 ppm group had delayed estrous cycles (6 days compared to 5 days in control rats). Noteworthy organ weight changes in rats of the 2000 ppm group included decreases in thymus, liver, and testicular weights; however, pathologic lesions were observed in the testes only. Sperm motility, epididymal sperm count, and testicular spermatid count were dramatically reduced. Microscopic lesions included degeneration of the seminiferous tubular cells, pyknosis or absence of germ cells, and hypospermia in the epididymis. Rats of the 600 ppm group had a slight decrease in thymic weight and a transient decrease in body weight. Results of the acute, 2-wk, and 13-wk inhalation studies indicate DMES concentrations of 1000 ppm and higher produce narcosis that rapidly disappears following exposure. Repeated exposure of rats to DMES at either 3000 ppm for 2 wk or 2000 ppm for 13 wk caused testicular atrophy and hypospermia in male rats. Female rats exposed to 2000 ppm for 13 wk had delayed estrous cycles. Toxicological effects in rats of the 600 ppm group were minimal and equivocal. The 160 ppm concentration was a no-observable-effect level (NOEL) for 13 wk of exposure to DMES.
- 1 January 1994
- Published by Taylor & Francis in Inhalation Toxicology
- Vol. 6 (2) , 151-166
Acute, 2-Week, and 13-Week Inhalation Toxicity Studies on Dimethylethoxysilane Vapor in Fischer 344 Rats
Dimethylethoxysilane (DMES), a volatile liquid, is used by NASA to waterproof the heat-protective silica tiles and blankets on the Space Shuttle. Acute, 2-wk, and 13-wk inhalation exposures to DMES vapor were conducted in male and female Fischer 344 rats. In the acute study, rats were exposed to 4000, 2000, 1000, 500, or 0 (control) ppm DMES for 4 h and observed for 14 days. There were no deaths. Narcosis and ataxia were observed in rats of the two highest concentrations only. These signs disappeared within 1 h following exposure. There were no DMES-related gross or microscopic tissue lesions in rats of all exposure groups. In the 2-wk study, rats were exposed for 6 h/day, 5 days/wk to 3000, 1000, 300, 100, or 0 ppm DMES. During exposure, narcosis was observed in rats of the 3000 and 1000 ppm groups. There was a mild decrease in body weight gain in rats of the 3000 ppm group. A decrease in platelet count, an increase in bile acids, and reduced weights of the thymus, testis, and liver were observed in rats of the 3000 ppm group. Microscopically, hypospermatogenesis and spermatid giant cells were observed in the seminiferous tubules of the testes of rats exposed to 3000 ppm DMES. In the 13-wk study, rats were exposed 6 h/day, 5 days/wk to 2000, 600, 160, 40, or 0 ppm DMES. During exposure, rats of the 2000 ppm group exhibited mild narcosis and loss of startle reflex. Recovery from these central nervous system signs was rapid. Body weights were mildly decreased for rats of the 2000 ppm group. There were no exposure-related effects in hematology, serum chemistry, or urinalysis. Female rats of the 2000 ppm group had delayed estrous cycles (6 days compared to 5 days in control rats). Noteworthy organ weight changes in rats of the 2000 ppm group included decreases in thymus, liver, and testicular weights; however, pathologic lesions were observed in the testes only. Sperm motility, epididymal sperm count, and testicular spermatid count were dramatically reduced. Microscopic lesions included degeneration of the seminiferous tubular cells, pyknosis or absence of germ cells, and hypospermia in the epididymis. Rats of the 600 ppm group had a slight decrease in thymic weight and a transient decrease in body weight. Results of the acute, 2-wk, and 13-wk inhalation studies indicate DMES concentrations of 1000 ppm and higher produce narcosis that rapidly disappears following exposure. Repeated exposure of rats to DMES at either 3000 ppm for 2 wk or 2000 ppm for 13 wk caused testicular atrophy and hypospermia in male rats. Female rats exposed to 2000 ppm for 13 wk had delayed estrous cycles. Toxicological effects in rats of the 600 ppm group were minimal and equivocal. The 160 ppm concentration was a no-observable-effect level (NOEL) for 13 wk of exposure to DMES.